Ligand Specificity in Fragment-Based Drug Design

被引:41
作者
Barelier, Sarah [1 ]
Pons, Julien [1 ]
Gehring, Kalle [2 ,3 ]
Lancelin, Jean-Marc [1 ]
Krimm, Isabelle [1 ]
机构
[1] Univ Lyon 1, Sci Analyt Lab, CNRS, ESCPE Lyon,UMR 5180, F-69100 Villeurbanne, France
[2] McGill Univ, Dept Biochem, Montreal, PQ H3G 0B1, Canada
[3] McGill Univ, Grp Rech Axe Struct Prot, Montreal, PQ H3G 0B1, Canada
关键词
BCL-2; FAMILY; POTENT INHIBITORS; LEAD GENERATION; NMR; DISCOVERY; BINDING; BCL-X(L); PROTEINS; PEROXIREDOXIN; AFFINITY;
D O I
10.1021/jm100496j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fragment-based drug design consists of identifying low-molecular weight compounds that weakly bind to a target macromolecule and will then be modified or linked to yield potent inhibitors. The specificity of these low-complexity and low-affinity molecules has rarely been discussed in the literature. To address this question, NMR spectroscopy was used to investigate the interactions of 150 fragments with five proteins: three proteins from the Bcl-2 family (Bcl-x(L), Bcl-w, and Mcl-1), human peroxiredoxin 5, for which very few ligands have been reported, and human serum albumin, which is known to bind a large number of ligands. Our results show that the fragments are rather versatile binders and able to identify binding hot spots in very different targets. Despite the different hit rates observed related to the druggability of the proteins, two scaffolds appear as preferred binders for all proteins. Low specificity was observed between homologous proteins or unrelated poorly druggable proteins, while higher specificity could be achieved with highly druggable targets.
引用
收藏
页码:5256 / 5266
页数:11
相关论文
共 66 条
[1]   The Bcl-2 apoptotic switch in cancer development and therapy [J].
Adams, J. M. ;
Cory, S. .
ONCOGENE, 2007, 26 (09) :1324-1337
[2]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[3]   Discovery of Fragment Molecules That Bind the Human Peroxiredoxin 5 Active Site [J].
Barelier, Sarah ;
Linard, Dominique ;
Pons, Julien ;
Clippe, Andre ;
Knoops, Bernard ;
Lancelin, Jean-Marc ;
Krimm, Isabelle .
PLOS ONE, 2010, 5 (03)
[4]   Fragment-Based Deconstruction of Bcl-xL Inhibitors [J].
Barelier, Sarah ;
Pons, Julien ;
Marcillat, Olivier ;
Lancelin, Jean-Marc ;
Krimm, Isabelle .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (06) :2577-2588
[5]   Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets [J].
Baurin, N ;
Aboul-Ela, F ;
Barril, X ;
Davis, B ;
Drysdale, M ;
Dymock, B ;
Finch, H ;
Fromont, C ;
Richardson, C ;
Simmonite, H ;
Hubbard, RE .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2004, 44 (06) :2157-2166
[6]   Properties of known drugs. 2. Side chains [J].
Bemis, GW ;
Murcko, MA .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (25) :5095-5099
[7]   Structural Insights into the Design of Small Molecule Inhibitors That Selectively Antagonize Mcl-1 [J].
Bernardo, Paul H. ;
Sivaraman, Thirunavukkarasu ;
Wan, Kah-Fei ;
Xu, Jin ;
Krishnamoorthy, Janarthanan ;
Song, Chun Meng ;
Tian, Liming ;
Chin, Jasmine S. F. ;
Lim, Diane S. W. ;
Mok, Henry Y. K. ;
Yu, Victor C. ;
Tong, Joo Chuan ;
Chai, Christina L. L. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (05) :2314-2318
[8]  
Bohacek RS, 1996, MED RES REV, V16, P3, DOI 10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.0.CO
[9]  
2-6
[10]   NMR screening applied to the fragment-based generation of inhibitors of creatine kinase exploiting a new interaction proximate to the ATP binding site [J].
Bretonnet, Anne-Sophie ;
Jochum, Anne ;
Walker, Olivier ;
Krimm, Isabelle ;
Goekjian, Peter ;
Marcillat, Olivier ;
Lancelin, Jean-Marc .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (08) :1865-1875